Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Ben Y DurkeeKathleen C Horst

Abstract

The Clinical Evaluation of Pertuzumab and Trastuzumab (CLEOPATRA) study showed a 15.7-month survival benefit with the addition of pertuzumab to docetaxel and trastuzumab (THP) as first-line treatment for patients with human epidermal growth factor receptor 2 (HER2) -overexpressing metastatic breast cancer. We performed a cost-effectiveness analysis to assess the value of adding pertuzumab. We developed a decision-analytic Markov model to evaluate the cost effectiveness of docetaxel plus trastuzumab (TH) with or without pertuzumab in US patients with metastatic breast cancer. The model followed patients weekly over their remaining lifetimes. Health states included stable disease, progressing disease, hospice, and death. Transition probabilities were based on the CLEOPATRA study. Costs reflected the 2014 Medicare rates. Health state utilities were the same as those used in other recent cost-effectiveness studies of trastuzumab and pertuzumab. Outcomes included health benefits expressed as discounted quality-adjusted life-years (QALYs), costs in US dollars, and cost effectiveness expressed as an incremental cost-effectiveness ratio. One- and multiway deterministic and probabilistic sensitivity analyses explored the effects of spec...Continue Reading

References

Jan 1, 1985·Medical Decision Making : an International Journal of the Society for Medical Decision Making·P DoubiletB J McNeil
Jul 18, 1996·The New England Journal of Medicine·N A Christakis, J J Escarce
Oct 9, 1996·JAMA : the Journal of the American Medical Association·L B RussellM C Weinstein
Sep 3, 1999·BMJ : British Medical Journal·A H Briggs, A M Gray
Jul 30, 2003·Archives of Internal Medicine·Peter A UbelA Mark Fendrick
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elena B ElkinJane C Weeks
Apr 29, 2004·JAMA : the Journal of the American Medical Association·Hadi YazijiAllen M Gown
Dec 22, 2005·The Oncologist·Joyce O'Shaughnessy
Feb 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicola Lucio LiberatoGiovanni Barosi
Feb 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Allison W KurianAlan M Garber
Jan 2, 2008·Annals of Internal Medicine·Anna N A TostesonUNKNOWN DMIST Investigators
Mar 8, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David CasarettDavid A Asch
Mar 11, 2009·Archives of Internal Medicine·Baohui ZhangHolly G Prigerson
Nov 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shaheenah DawoodSharon H Giordano
Jan 14, 2011·Journal of the National Cancer Institute·Angela B MariottoMartin L Brown
Dec 14, 2011·The New England Journal of Medicine·José BaselgaUNKNOWN CLEOPATRA Study Group
Sep 20, 2012·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Andrew H BriggsUNKNOWN ISPOR-SMDM Modeling Good Research Practices Task Force
Sep 20, 2012·Medical Decision Making : an International Journal of the Society for Medical Decision Making·David M EddyUNKNOWN ISPOR-SMDM Modeling Good Research Practices Task Force
Apr 20, 2013·Journal of Oncology Practice·Benjamin ChastekApril H Teitelbaum
Jul 23, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J CortésS M Swain
Feb 19, 2015·The New England Journal of Medicine·Sandra M SwainUNKNOWN CLEOPATRA Study Group

❮ Previous
Next ❯

Citations

Aug 16, 2016·The Breast : Official Journal of the European Society of Mastology·Michael J DuffyJohn Crown
Nov 25, 2016·Expert Review of Anticancer Therapy·Matteo LambertiniEvandro de Azambuja
Jan 27, 2017·Journal of Managed Care & Specialty Pharmacy·Leslie WilsonKevin Rodondi
Sep 10, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter B Bach
Mar 16, 2017·Nature Reviews. Clinical Oncology·Vinay PrasadSham Mailankody
Jul 28, 2016·Einstein·Rafael Aliosha Kaliks
Jan 27, 2017·Journal of Immunotherapy·Gennaro RiccioClaudia De Lorenzo
Jul 2, 2017·Neuro-oncology·Yushen QianScott G Soltys
Oct 3, 2017·Expert Review of Pharmacoeconomics & Outcomes Research·Henry W C LeungJohn Hang Leung
May 22, 2018·Expert Review of Anticancer Therapy·Mariana BrandãoEvandro de Azambuja
Feb 2, 2018·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Henry Wc LeungShyh-Yau Wang
Dec 19, 2016·F1000Research·Daniel A Vorobiof
Jan 9, 2019·Journal of Comparative Effectiveness Research·Tine GeldofIsabelle Huys
Jun 1, 2017·American Society of Clinical Oncology Educational Book·Gabriel A BrooksRavi Salgia
Nov 7, 2019·Applied Health Economics and Health Policy·Caridad PontesBrian Godman
Dec 6, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jinani Jayasekera, Jeanne S Mandelblatt
Feb 19, 2020·CA: a Cancer Journal for Clinicians·Javier CortesJoaquín Arribas
Aug 23, 2019·Breast Cancer Research and Treatment·Nicolò Matteo Luca BattistiIan Smith
Dec 1, 2017·Expert Opinion on Biological Therapy·Jack Patrick GleesonPatrick G Morris
Apr 3, 2019·Future Oncology·Daniel EigerEvandro de Azambuja
Aug 27, 2019·Expert Review of Anticancer Therapy·Giulia VialeGiuseppe Curigliano
Mar 8, 2017·Annals of Surgery·Gaya SpolveratoTimothy M Pawlik
Sep 22, 2018·Clinical & Experimental Metastasis·Mariz KasohaErich-Franz Solomayer
Mar 20, 2019·Expert Review of Anticancer Therapy·Marie RobertMario Campone
Oct 1, 2016·Israel Journal of Health Policy Research·Daniel A GoldsteinNoa Gordon
Jan 4, 2019·Breast Cancer Research and Treatment·Anagha GogateStephanie B Wheeler
Sep 27, 2019·Journal of Managed Care & Specialty Pharmacy·Naomi R M SchwartzJoshua A Roth
Nov 21, 2020·Expert Review of Pharmacoeconomics & Outcomes Research·Vakaramoko DiabyAskal Ali
Feb 5, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Vinay VaradanLyndsay N Harris
Jan 29, 2021·Japanese Journal of Clinical Oncology·Nobuyasu AwanoHideo Kunitoh
Mar 2, 2021·Expert Review of Pharmacoeconomics & Outcomes Research·Boshen Jiao, Louis P Garrison
Mar 10, 2021·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Gursharan K SohiNatalie G Coburn
Apr 26, 2021·The Breast : Official Journal of the European Society of Mastology·Antonio Olry de Labry LimaEmilio Jesús Alegre Del Rey
May 5, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H MamiyaM Najafzadeh

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.